Inhalant dependence, in remission
ICD-10 F18.21 is a billable code used to indicate a diagnosis of inhalant dependence, in remission.
Inhalant dependence refers to a pattern of inhalant use that leads to clinically significant impairment or distress. This condition is characterized by a strong desire or compulsion to use inhalants, tolerance to their effects, and withdrawal symptoms upon cessation. Inhalants include a variety of substances such as solvents, aerosols, and gases that are inhaled for their psychoactive effects. When a patient is diagnosed with inhalant dependence, in remission, it indicates that they have previously met the criteria for inhalant dependence but are currently not experiencing symptoms or have not used inhalants for a specified period, typically at least 12 months. This remission status is crucial for treatment planning and monitoring, as it reflects the patient's progress and the effectiveness of interventions aimed at reducing substance use. Treatment may involve behavioral therapies, counseling, and support groups, focusing on relapse prevention and coping strategies. Understanding the nuances of inhalant dependence and its remission is essential for accurate coding and effective patient management.
Comprehensive history of substance use, treatment plans, and progress notes.
Patients presenting with inhalant use history, undergoing detoxification, or in outpatient therapy.
Ensure documentation reflects the patient's current status and any co-occurring disorders.
Mental health evaluations, treatment response assessments, and follow-up notes.
Patients with inhalant dependence presenting with anxiety or mood disorders.
Document any psychiatric evaluations that address the impact of inhalant use on mental health.
Used during initial evaluation of a patient with a history of inhalant dependence.
Document the assessment findings and treatment recommendations.
Addiction specialists should ensure comprehensive evaluations are performed.
In remission indicates that the patient has not used inhalants for a specified period, typically at least 12 months, and is not experiencing any symptoms related to inhalant dependence.
